A recent study suggests that patients with myelodysplastic syndrome (MDS) could potentially benefit from allogeneic hematopoietic cell transplantation (HCT) regardless of genetic mutation status.

Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 ...

Regarding overall survival, allogeneic HCT did not have a benefit over consolidation chemotherapy in patients with intermediate-risk disease. Allogeneic hematopoietic cell transplantation (HCT) during ...

For patients with acute myeloid leukemia (AML), immediate allogeneic hematopoietic stem cell transplantation (HCT) after primary induction failure (PIF) offers long-term survival benefit, according to ...

Allogeneic hematopoietic cell transplantation (allo-HCT) is feasible in older patients with myelodysplastic syndrome (MDS), according to a study published online June 26 in the European Journal of ...

Allogeneic hematopoietic stem cell transplantation (HCT) is currently the standard of care for most patients with high-risk acute leukemias and some other hematologic malignancies. Although HCT can be ...

The OS and GEFS of the study cohort. The solid line and the dashed line show OS and GEFS curves, respectively. OS and GEFS at 2 years post-HCT are described with 95% confidence intervals in brackets.

Please provide your email address to receive an email when new articles are posted on . Patients who received stem cell grafts from unrelated donors matched at as few as 4/8 HLA markers achieved ...

—Patients with AML who undergo HCT have variable outcomes, including NRM and relapse. Having tools to predict post-HCT outcomes would help estimate risks and potential survival of individual patients.